Since CML is caused by this distinct genetic lesion it was possible to design an effective targeted molecular therapy which selectively inhibits the aberrant BCR-ABL tyrosine kinase. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.